Early economic evaluation of an intervention to improve uptake of the NHS England Diabetes Prevention Programme. (3rd April 2022)
- Record Type:
- Journal Article
- Title:
- Early economic evaluation of an intervention to improve uptake of the NHS England Diabetes Prevention Programme. (3rd April 2022)
- Main Title:
- Early economic evaluation of an intervention to improve uptake of the NHS England Diabetes Prevention Programme
- Authors:
- Frempong, Samuel N
Shinkins, Bethany
Howdon, Daniel
Messenger, Michael
Neal, Richard D
Sagoo, Gurdeep S - Abstract:
- ABSTRACT: Background: Despite reported increases in referral numbers, a large proportion of those with prediabetes still decline participation in the NHS England Diabetes Prevention Programme (NDPP). The aim of this study was to explore whether investment in interventions to improve uptake of the programme has the potential to be cost-effective. Methods: An early cost-utility analysis was conducted using a Markov model parameterized based on secondary data sources. We explored different uptake scenarios and the impact that this had on the maximum allowable intervention price based on cost-effectiveness at the UK NICE willingness to pay threshold of £20, 000 (US$ 25, 913). Value of information analyses were conducted to explore the potential value of further research to resolve uncertainty at each uptake level. Results: As uptake levels increase, the maximum allowable intervention price and overall expected value of removing decision uncertainty increases. For 5 percentage and 50 percentage points increase in uptake levels, the maximum allowable intervention price is £41.86 (US$ 54.23) and £418.59 (US$ 542.34) per person, and the overall expected value of removing decision uncertainty are £361, 818, 839 (US$ 468, 786, 625) and £1, 468, 712, 316 (US$ 1, 902, 921, 063) respectively. Conclusion: There is headroom for investment in interventions that improve uptake to the NDPP, thereby allowing the programme itself to be delivered in a manner that remains cost-effective.
- Is Part Of:
- Expert review of pharmacoeconomics & outcomes research. Volume 22:Number 3(2022)
- Journal:
- Expert review of pharmacoeconomics & outcomes research
- Issue:
- Volume 22:Number 3(2022)
- Issue Display:
- Volume 22, Issue 3 (2022)
- Year:
- 2022
- Volume:
- 22
- Issue:
- 3
- Issue Sort Value:
- 2022-0022-0003-0000
- Page Start:
- 417
- Page End:
- 427
- Publication Date:
- 2022-04-03
- Subjects:
- Early economic evaluation -- headroom analysis -- NHS Diabetes Prevention Programme -- prediabetes -- Type 2 diabetes mellitus -- value of information analysis
Pharmacology -- Economic aspects -- Periodicals
338.47615105 - Journal URLs:
- http://www.future-drugs.com/loi/erp ↗
http://informahealthcare.com ↗ - DOI:
- 10.1080/14737167.2021.1895755 ↗
- Languages:
- English
- ISSNs:
- 1473-7167
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 3842.002996
British Library DSC - BLDSS-3PM
British Library HMNTS - Digital store
British Library HMNTS - ELD Digital store - Ingest File:
- 21248.xml